Outlook Therapeutics trims staff and recalibrates its regulatory strategy after its wet AMD trial falls short, underscoring the …
Outlook Therapeutics trims staff and recalibrates its regulatory strategy after its wet AMD trial falls short, underscoring the …
Novo Nordisk’s oral obesity drug shows superior efficacy over Eli Lilly’s candidate, reshaping the competitive landscape in metabolic …
With all three Phase 3 trials now enrolling, Akero Therapeutics is racing to bring its promising MASH therapy, …
Facing partnership setbacks and pipeline pressure, Editas Medicine lays off 65% of its staff and pivots toward its …
With a fresh $153 million in funding, Strand Therapeutics is pushing the boundaries of mRNA technology—this time, in …
With a landmark $277 million raise, Element Biosciences is scaling its AVITI™ platform and diving deep into multi-omics—reshaping …
In a surprising move, Novartis snapped up preclinical-stage Kate Therapeutics for over a billion dollars—signaling renewed confidence in …
Despite a muted IPO market and cautious M&A activity, biotech in 2024 proved that innovation never sleeps—especially when …
From schizophrenia to sleep apnoea, 2024 closes with landmark approvals that could redefine treatment standards across multiple therapeutic …
Exploring recent advancements in CRISPR therapies, personalized gene editing, and artificial intelligence transforming drug development and clinical trials.
